靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）两个表位的抗体可中和携带不同变体刺突蛋白的假病毒。

Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants.

作者信息

Yang Chee-Hing, Li Hui-Chun, Lee Wen-Han, Lo Shih-Yen

机构信息

Department of Laboratory Medicine and Biotechnology, Tzu Chi University, Hualien 97004, Taiwan.

Department of Biochemistry, Tzu Chi University, Hualien 97004, Taiwan.

出版信息

Pathogens. 2021 Jul 9;10(7):869. doi: 10.3390/pathogens10070869.

DOI:10.3390/pathogens10070869

PMID:34358019

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8308897/

Abstract

The COVID-19 pandemic was caused by SARS-CoV-2 infection. To prevent the spread of SARS-CoV-2, an effective vaccine is required. Two linear peptides from potential B-cell epitopes in the spike protein of SARS-CoV-2 (a.a. 440-460; a.a. 494-506) were synthesized and used to immunize rabbits. High-titer antibodies of IgG were produced, purified, and verified by Western blot analysis. Antibodies against these two epitopes could effectively neutralize SARS-CoV-2 pseudoviral particles with the spike proteins from not only the original strain (basal; wild-type), but also a strain with a single point mutation (D614G), and two other emerging variants (the Alpha and Beta variants) prevalent around the world, but not from SARS-CoV. In conclusion, antibodies against these two epitopes are protective. This information is important for the development of vaccines against SARS-CoV-2.

摘要

新冠疫情由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染所致。为防止SARS-CoV-2传播，需要一种有效的疫苗。合成了来自SARS-CoV-2刺突蛋白中潜在B细胞表位的两种线性肽（氨基酸440 - 460；氨基酸494 - 506），并用于免疫兔子。产生了高滴度的IgG抗体，进行了纯化，并通过蛋白质印迹分析进行了验证。针对这两个表位的抗体不仅可以有效中和具有来自原始毒株（基础型；野生型）刺突蛋白的SARS-CoV-2假病毒颗粒，还可以中和具有单点突变（D614G）的毒株以及全球流行的另外两种新出现的变异株（Alpha和Beta变异株）的SARS-CoV-2假病毒颗粒，但不能中和来自SARS-CoV的假病毒颗粒。总之，针对这两个表位的抗体具有保护作用。该信息对于开发抗SARS-CoV-2疫苗很重要。